RNA News and Research

RSS

Ribonucleic acid (RNA) is a biologically important type of molecule that consists of a long chain of nucleotide units. Each nucleotide consists of a nitrogenous base, a ribose sugar, and a phosphate.

Scientists develop new method to directly identify miRNA targets in cells

Human cells are thought to produce thousands of different microRNAs (miRNAs)-small pieces of genetic material that help determine which genes are turned on or off at a given time. miRNAs are an important part of normal cellular function, but they can also contribute to human disease-some are elevated in certain tumors, for example, where they promote cell survival.

10 May 2012

Inovio first quarter total revenue decreases to $1.7 million

Inovio Pharmaceuticals, Inc. today reported financial results for the quarter ended March 31, 2012.

10 May 2012

Human Gene Therapy highlights new advances in human retinal disease

Gene therapy strategies to prevent and treat inherited diseases of the retina that can cause blindness have progressed rapidly. Positive results in animal models of human retinal disease continue to emerge, as reported in several articles published in Human Gene Therapy, a peer-reviewed journal from Mary Ann Liebert, Inc., publishers.

9 May 2012

GenMark Diagnostics first quarter revenues increase to $2.2M

GenMark Diagnostics, Inc. today reported financial results for the first quarter ended March 31, 2012.

9 May 2012

Research grants on facioscapulohumeral dystrophy prove useful as genetic basis is found

Businessman Bill Moss’s determination to fight his untreatable muscle-wasting disease may have paid off. Four years ago, Mr Moss, a former Macquarie Bank Executive Director, established a charitable research foundation, FSHD Global, which partly funded the Italian researchers who made the breakthrough.

8 May 2012

Hologic features minimally invasive technologies at ACOG annual clinical meeting

Hologic, Inc., a leading developer, manufacturer and supplier of premium diagnostics products, medical imaging systems and surgical products dedicated to serving the healthcare needs of women, is featuring minimally invasive technologies in surgical, diagnostic and skeletal health at The American College of Obstetricians and Gynecologists (ACOG) annual clinical meeting.

From Hologic, Inc. 7 May 2012

Data from Idera IMO-8400 preclinical studies for SLE and psoriasis presented at AAI meeting

Idera Pharmaceuticals, Inc. today announced data from preclinical studies of IMO-8400, demonstrating a novel mechanism of action that may be applicable to the treatment of systemic lupus erythematosus (SLE) and psoriasis. IMO-8400 is an inhibitor of specific Toll-like receptors (TLRs).

7 May 2012

BioCryst first quarter revenues increase to $12.2 million

BioCryst Pharmaceuticals, Inc. announced financial results for the first quarter ended March 31, 2012.

7 May 2012

Researchers separate low and high-PSA prostate cancer cells

Prostate cancer cells that defy treatment and display heightened tumor-generating capacity can be identified by levels of prostate specific antigen (PSA) expressed in the tumor cells, a research team led by scientists at The University of Texas MD Anderson Cancer Center reports in the May 3 edition of Cell Stem Cell.

7 May 2012

Dilp8 provides an important signal to slow body growth and delay insect development

Two independent groups of researchers have identified a hormone that is responsible for keeping the growth and development of insects on track. The results, which are reported in the journal Science, suggest that Dilp8 provides an important signal to slow body growth and delay insect development.

5 May 2012

MicroRNAs in breast cancer play a role in development of resistance to tamoxifen

Many breast cancer patients are treated with a drug called tamoxifen. The substance blocks the effect of estrogen and thus suppresses the growth signals of this hormone in cancer cells. When resistance to the drug develops, tumor cells change their growth program: They change their behavior and shape, become more mobile and also adopt the ability to invade surrounding tissue. Scientists working with PD (Associate Professor) Dr. Stefan Wiemann of the German Cancer Research Center (DKFZ) have now also observed these changes in tamoxifen resistant breast cancer cells.

5 May 2012

New light on many biological differences between individual breast cancers

New findings presented at Europe's leading breast cancer translational research conference this year shed new light on the many biological differences between individual breast cancers.

4 May 2012

Alnylam first quarter revenues decrease to $20.6 million

Alnylam Pharmaceuticals, Inc., a leading RNAi therapeutics company, today reported its consolidated financial results for the first quarter 2012, and company highlights.

4 May 2012

Affymetrix total revenue decreases to $65.2 million

Affymetrix, Inc., today reported its operating results for the first quarter of 2012. Total revenue for the quarter was $65.2 million, as compared to total revenue of $73.7 million for the same period of 2011.

4 May 2012

Hypoxia may be a primary cause of uncontrollable tumor growth in cancers

Low oxygen levels in cells may be a primary cause of uncontrollable tumor growth in some cancers, according to a new University of Georgia study. The authors' findings run counter to widely accepted beliefs that genetic mutations are responsible for cancer growth.

4 May 2012

Affymetrix to acquire eBioscience

Affymetrix, Inc., and eBioscience, Inc., a privately-held San Diego, CA-based company with an industry-leading position in flow cytometry and immunoassay reagents for immunology and oncology research and diagnostics, today announced they have amended their existing definitive agreement dated November 29, 2011 under which Affymetrix will acquire eBioscience.

4 May 2012

Novel stem cell transplantation holds promise for HIV prevention

UC Davis Health System researchers are a step closer to launching human clinical trials involving the use of an innovative stem cell therapy to fight the virus that causes AIDS.

3 May 2012

Cancer genomes in a common database and computation of disease drivers

The emerging field of "personalized" or "precision" medicine holds great promise in the fight against cancer. If scientists can identify the genetic changes that drive each patient's cancer cells, they can use that information to develop targeted treatments. But achieving this goal will require massive amounts of genomic and clinical data and a sophisticated infrastructure to manage and analyze the data.

2 May 2012

Trovagene completes PCR assay development for detection of K-RAS mutations

Trovagene, Inc., a developer of trans-renal molecular diagnostics, announced today that the Company has successfully completed the analytical development of digital PCR assays for the detection of the most prevalent K-RAS mutations, which are, according to recent estimates, observed in more than 90% of pancreatic cancers, and in 23% of all solid tumors.

30 Apr 2012

Hologic second quarter revenues increase 7.4% to $471.2 million

Hologic, Inc., a leading developer, manufacturer and supplier of premium diagnostics products, medical imaging systems and surgical products dedicated to serving the healthcare needs of women, today announced its results for the second fiscal quarter ended March 24, 2012.

From Hologic, Inc. 30 Apr 2012